Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26669665 | 0.81 | ALDH1A1 (0.33) | ALDH1A1GAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21929803 | 0.79 | AHR (0.37) | ALDH1A1GAA | |
| SCHEMBL27476855 | 0.75 | ALDH1A1 (0.40) | ALDH1A1GAALMNA | |
| SCHEMBL15686694 | 0.73 | SCN5A (0.40) | ALDH1A1SMN1; SMN2LMNATRPA1PTGS1 | |
| SCHEMBL13086576 | 0.73 | ALDH1A1 (0.36) | ALDH1A1GAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13086389 | 0.72 | MEN1 (0.32) | ALDH1A1NPC1RAB9A | |
| SCHEMBL21103957 | 0.72 | NOTUM (0.36) | LMNANOTUM | |
| SCHEMBL798445 | 0.69 | ALDH1A1 (0.33) | ALDH1A1GAA | |
| SCHEMBL19619534 | 0.69 | — | — | |
| SCHEMBL31001773 | 0.69 | UGT2B7 (0.34) | ALDH1A1GAARAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389008-A1 | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | ALDH1A1 1242/4885GAA 1686/4885NPC1 2134/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | ALDH1A1 3750/4885GAA 1336/4885NPC1 1283/4885 |
| US-20220389008-A1 | 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS | NQO2, NDUFS3, QARS1 | ALDH1A1 1097/4885GAA 389/4885NPC1 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.